Physician profile
Ahmad Emami
NPI 1760463558
$1,995.17
in general payments reported to CMS, 2019-2025
12 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $158 · 2021: $181 · 2022: $318 · 2023: $402 · 2024: $303 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $687.62 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $416.01 | 2019-2023 | |
| Amarin Pharma, INC. | $336.51 | 2020-2023 | |
| Glaxosmithkline, LLC. | $212.52 | 2023-2025 | Arexvy, Trelegy Ellipta |
| Boston Scientific Corporation | $148.48 | 2024 | Ams 700 Cxr Rte Kit |
| Edwards Lifesciences Corporation | $81.35 | 2019 | |
| Pfizer INC. | $45.00 | 2025 | |
| Allergan, INC. | $19.18 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.71 | 2022 | |
| Lilly USA, LLC | $13.75 | 2025 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.73 | 2022 | |
| Dynavax Technologies Corporation | $7.31 | 2024 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Emami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.